Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D006585:Altretamine / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011344:Procarbazine / Q000627:therapeutic use; D014227:Triazines / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D014227:Triazines; D001761:Bleomycin; D011344:Procarbazine; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D006585:Altretamine; D008727:Methotrexate